BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) announced its earnings results on Wednesday. Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:Get BioCryst Pharmaceuticals alerts:ORLADEYO revenue rose 10% year over year to $158.2 million on a comparable basis, with continued new-prescriber additions, stable demand and an improved paid rate of 84%. BioCryst Pharmaceuticals Trading Up 1.2%Shares of BioCryst Pharmaceuticals stock traded up $0.11 on Friday, reaching $9.41. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.22. See AlsoReceive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.